Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1]It is the largest pharmaceutical company in India.[2]
Product OfferingsThe company produces a range of generic and specialty medications for chronic and acute conditions. Its product portfolio includes generics, branded generics, specialty pharmaceuticals, advanced technology-based products, antiretrovirals, active pharmaceutical ingredients (APIs), and intermediates. It offers medications in multiple dosage forms, such as injectables, sprays, ointments, creams, liquids, tablets, and capsules.[1][2]The company offers 26+ products in the global specialty market, with a strategic focus on dermatology, ophthalmology, and onco-dermatology segments.[3]
| S.No. | Name | Current Price (Rs.) | Price to Earning | Market Capitalization (Rs.Cr.) | Dividend yield (%) | Net Profit latest quarter (Rs.Cr.) | YOY Quarterly profit growth (%) | Sales latest quarter (Rs.Cr.) | YOY Quarterly sales growth (%) | Return on capital employed (%) | Sales (Rs.Cr.) | OPM (%) | Profit after tax (Rs.Cr.) | Profit after tax latest quarter (Rs.Cr.) | Price to book value | Return on assets (%) | Debt to equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Sun Pharma.Inds. | 1668.90 | 85.70 | 400460.33 | 0.96 | 564.22 | -32.70 | 4548.11 | -11.21 | 16.80 | 23520.54 | 33.10 | 4672.99 | 564.22 | 16.82 | 10.14 | 0.56 |
| 2. | Divi's Lab. | 6236.00 | 66.61 | 165513.66 | 0.48 | 689.00 | 35.10 | 2715.00 | 16.12 | 20.44 | 10029.00 | 32.37 | 2485.00 | 689.00 | 10.74 | 13.53 | 0.01 |
| 3. | Torrent Pharma. | 4018.20 | 62.75 | 135955.09 | 0.80 | 591.00 | 32.49 | 3302.00 | 14.30 | 27.05 | 12248.00 | 32.60 | 2166.53 | 600.17 | 16.10 | 13.26 | 0.33 |
| 4. | Cipla | 1397.50 | 20.75 | 112878.16 | 0.93 | 1353.37 | 3.73 | 7589.44 | 7.64 | 22.72 | 28349.57 | 25.40 | 5441.14 | 1351.17 | 3.43 | 14.72 | 0.01 |
| 5. | Lupin | 2177.90 | 23.01 | 99527.00 | 0.55 | 1484.83 | 73.34 | 7047.51 | 24.23 | 21.30 | 24750.69 | 27.25 | 4324.63 | 1477.92 | 5.07 | 12.41 | 0.32 |
| 6. | Dr Reddy's Labs | 1175.50 | 17.00 | 98114.93 | 0.68 | 1336.80 | 7.28 | 8828.30 | 9.83 | 22.69 | 34310.00 | 24.64 | 5772.20 | 1347.10 | 2.72 | 12.95 | 0.16 |
| 7. | Mankind Pharma | 2175.40 | 51.37 | 89821.63 | 0.05 | 520.18 | -22.00 | 3697.16 | 20.77 | 15.98 | 13545.67 | 24.12 | 1748.55 | 511.51 | 5.87 | 8.89 | 0.55 |
| – | Median: 149 Co. | 392.6 | 30.0 | 1767.16 | 0.12 | 13.96 | 10.46 | 161.76 | 10.58 | 14.89 | 603.85 | 15.93 | 45.26 | 14.12 | 3.13 | 8.56 | 0.22 |
Standalone figures in ₹ crores
| Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 5,285 | 4,646 | 5,948 | 4,466 | 5,096 | 5,074 | 5,639 | 4,498 | 5,122 | 6,192 | 7,186 | 5,595 | 4,548 |
Expenses | 3,622 | 3,646 | 3,588 | 3,517 | 3,710 | 3,715 | 3,746 | 3,737 | 3,791 | 4,488 | 4,196 | 3,685 | 3,365 |
Operating Profit | 1,663 | 999 | 2,361 | 949 | 1,386 | 1,359 | 1,894 | 761 | 1,332 | 1,703 | 2,989 | 1,910 | 1,184 |
Other Income | 42 | 68 | -2,817 | 14 | 107 | 7 | 119 | 83 | 95 | 68 | 132 | -184 | 73 |
Profit before tax | 1,228 | 506 | -1,030 | 390 | 907 | 751 | 1,402 | 258 | 871 | 1,265 | 2,612 | 1,176 | 672 |
Tax % | 1% | 4% | -1% | 2% | 2% | 4% | 38% | 8% | 4% | 7% | 23% | 37% | 16% |
Net Profit | 1,213 | 487 | -1,021 | 381 | 889 | 721 | 868 | 238 | 838 | 1,181 | 2,000 | 745 | 564 |
EPS in Rs | 5.06 | 2.03 | -4.25 | 1.59 | 3.70 | 3.01 | 3.62 | 0.99 | 3.49 | 4.92 | 8.34 | 3.11 | 2.35 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 2,829 | 8,028 | 7,719 | 7,684 | 8,982 | 10,303 | 12,532 | 14,116 | 15,586 | 20,812 | 20,275 | 23,003 | 23,521 |
Expenses | 2,810 | 8,581 | 8,130 | 7,559 | 7,998 | 8,513 | 9,815 | 11,849 | 12,917 | 14,389 | 14,761 | 16,465 | 15,734 |
Operating Profit | 19 | -552 | -410 | 125 | 985 | 1,790 | 2,717 | 2,267 | 2,669 | 6,423 | 5,514 | 6,538 | 7,786 |
Other Income | -2,700 | 205 | 367 | 504 | 171 | 23 | 1,506 | 93 | -624 | -2,609 | 320 | 624 | 89 |
Interest | 18 | 551 | 574 | 224 | 388 | 541 | 408 | 268 | 388 | 472 | 784 | 893 | 920 |
Depreciation | 102 | 661 | 464 | 422 | 487 | 553 | 562 | 1,236 | 1,350 | 1,601 | 1,601 | 1,238 | 1,230 |
Profit before tax | -2,801 | -1,559 | -1,082 | -17 | 280 | 719 | 3,253 | 856 | 307 | 1,741 | 3,450 | 5,031 | 5,725 |
Net Profit | -2,829 | -1,474 | -1,088 | -23 | 306 | 817 | 3,211 | 842 | -100 | 1,691 | 2,858 | 4,283 | 4,491 |
EPS in Rs | -13.66 | -7.12 | -4.52 | -0.10 | 1.27 | 3.40 | 13.38 | 3.51 | -0.42 | 7.05 | 11.91 | 17.85 | 18.72 |
Dividend Payout % | -11% | -42% | -22% | -3,677% | 157% | 81% | 30% | 214% | -2,400% | 163% | 113% | 90% | – |
Standalone figures in ₹ crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 207 | 207 | 241 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 |
Reserves | 7,201 | 22,579 | 21,650 | 20,773 | 22,083 | 22,604 | 24,156 | 26,699 | 24,348 | 23,508 | 23,454 | 24,100 | 23,573 |
Borrowings | 2,409 | 6,811 | 5,829 | 6,047 | 6,884 | 6,437 | 6,406 | 7,358 | 5,074 | 7,791 | 11,227 | 11,138 | 13,339 |
Other Liabilities | 4,548 | 7,849 | 6,547 | 6,810 | 7,585 | 8,434 | 7,608 | 9,438 | 11,103 | 9,448 | 6,143 | 7,796 | 8,267 |
Total Liabilities | 14,364 | 37,446 | 34,266 | 33,869 | 36,792 | 37,714 | 38,410 | 43,735 | 40,765 | 40,987 | 41,065 | 43,273 | 45,419 |
Fixed Assets | 1,267 | 3,185 | 3,575 | 4,039 | 4,645 | 4,978 | 5,229 | 9,669 | 9,713 | 8,712 | 7,737 | 6,989 | 7,836 |
Gross Block | 1,974 | 5,995 | 4,104 | 4,988 | 6,573 | 7,461 | 8,245 | 15,812 | 17,195 | 17,745 | 18,252 | 18,627 | – |
Accumulated Depreciation | 706 | 2,810 | 529 | 949 | 1,928 | 2,483 | 3,016 | 6,144 | 7,482 | 9,033 | 10,515 | 11,639 | – |
CWIP | 480 | 1,091 | 768 | 1,100 | 988 | 643 | 597 | 1,090 | 829 | 853 | 766 | 939 | 769 |
Investments | 7,016 | 25,876 | 22,372 | 19,333 | 18,355 | 17,904 | 17,362 | 15,537 | 15,549 | 12,613 | 12,430 | 12,410 | 12,579 |
Other Assets | 5,601 | 7,294 | 7,552 | 9,397 | 12,804 | 14,189 | 15,223 | 17,438 | 14,675 | 18,810 | 20,132 | 22,936 | 24,235 |
Total Assets | 14,364 | 37,446 | 34,266 | 33,869 | 36,792 | 37,714 | 38,410 | 43,735 | 40,765 | 40,987 | 41,065 | 43,273 | 45,419 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operating Activity | -2,405 | 149 | -1,254 | -1,621 | -1,171 | 1,242 | 1,306 | -417 | 7,636 | 507 | -292 | 4,199 |
Cash from Investing Activity | 517 | 2,642 | 3,640 | 2,381 | 1,394 | 431 | 1,483 | 1,452 | -2,697 | -686 | -265 | -202 |
Cash from Financing Activity | 1,742 | -2,674 | -2,368 | -753 | -272 | -1,469 | -2,871 | -1,000 | -4,871 | 169 | 474 | -3,831 |
Net Cash Flow | -145 | 117 | 17 | 7 | -50 | 205 | -82 | 36 | 68 | -9 | -84 | 166 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 126 | 82 | 94 | 129 | 214 | 178 | 180 | 170 | 99 | 125 | 159 | 186 |
Inventory Days | 315 | 227 | 260 | 256 | 218 | 277 | 210 | 245 | 220 | 240 | 223 | 231 |
Days Payable | 130 | 164 | 216 | 229 | 262 | 214 | 170 | 288 | 175 | 188 | 171 | 210 |
Cash Conversion Cycle | 311 | 146 | 138 | 155 | 170 | 242 | 220 | 127 | 144 | 177 | 211 | 207 |
Working Capital Days | 60 | -278 | -168 | -227 | -129 | -95 | -9 | 62 | -26 | 131 | 182 | -5 |
ROCE % | 0% | -6% | -3% | -0% | 5% | 8% | 11% | 4% | 8% | 17% | 13% | 17% |
Direct from BSE filings, auto-summarised
External media mentions & references
Editorial & research coverage
Nov 2025
Sep 2025
Jul 2025
May 2025
Mar 2025
Jan 2025
Nov 2024
Oct 2024
Sep 2024
Aug 2024
May 2024
Mar 2024
Feb 2024
Jan 2024
Nov 2023
Sep 2023
Aug 2023
May 2023
Apr 2023
Feb 2023
Nov 2022
Sep 2022
Aug 2022
Jun 2022
Mar 2022
Feb 2022
Nov 2021
Aug 2021
Aug 2021
Jun 2021
Jan 2021
Oct 2020
Stock Analysis
Sun Pharmaceutical Industries Limited is India's largest pharmaceutical company, specializing in branded and generic formulations and APIs. It has a significant presence in innovative medicines, particularly in dermatology, ophthalmology, and onco-dermatology, serving over 100 countries.
The US availability of UNLOXCYT™ (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma (aCSCC) is a key growth trigger, bolstering Sun Pharma's oncology pipeline. The drug's unique mechanism, durable efficacy, and updated FDA label with strong patient support programs aim to drive significant revenue contribution from its innovative medicines segment.
Currently no data available for Order Book.
While adverse reactions for UNLOXCYT™ are noted as common, they are generally mild. The drug has a limited distribution network. Broader company concerns include past US FDA facility compliance issues.
The press release announcing UNLOXCYT™ availability is dated January 15, 2026. No further specific future dates are mentioned in this announcement.
Corporate Announcements
